

04-28-06

IFW

CASE ON/4-32701A



FILING BY "EXPRESS MAIL" UNDER 37 CFR 1.10

EV727274532 45  
Express Mail Label Number

April 27, 2006  
Date of Deposit

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE PCT NATIONAL STAGE APPLICATION OF

DAVID BRYANT BATT

INTERNATIONAL APPLICATION NO: PCT/EP03/10675

FILED: 25 SEPTEMBER 2003

U.S. APPLICATION NO: 10/528,915 ✓

35 USC §371 DATE: 5 JANUARY 2006

FOR: PCR BASED DIAGNOSTIC METHOD OF DETECTING A  
MUTATION IN A NUCLEIC ACID

**MS: Amendment**

Commissioner for Patents

PO Box 1450

Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

Applicant believes this paper is being filed before the mailing date of a first Office action on the merits, and so under 37 C.F.R. §1.97(b)(3) no fees are required. If a fee is deemed to be required, the Commissioner is hereby authorized to charge such fee to Deposit Account No. 19-0134.


In accordance with 37 C.F.R. §1.56, applicant wishes to call the Examiner's attention to the references cited on the attached form(s) PTO-1449.

Copies of these references are enclosed herewith.

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO 1449 form(s).

Respectfully submitted,

Novartis  
Corporate Intellectual Property  
One Health Plaza, Building 104  
East Hanover, NJ 07936-1080  
(862) 778-7898

  
Lydia T. McNally  
Attorney for Applicant  
Reg. No. 36,214


Date: *April 27, 2006*

FORM PTO-1449  
(REV. 7-85)U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.  
ON/4-32701A  
APPLICATION NO.  
10/528,915  
APPLICANT  
David Bryant Batt  
FILING DATE  
JANUARY 5, 2006

Group

## INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)



## U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
AA	5,981,731	11/09/99	Monia	536	24.5	07/07/97
AB						
AC						
AD						
AE						
AF						
AG						
AH						
AI						
AJ						
AK						
AL						

## FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
AM	WO 94/15645	07/21/94	WO			<input type="checkbox"/>	<input type="checkbox"/>
AN	WO 99/02167	01/21/99	WO			<input type="checkbox"/>	<input type="checkbox"/>
AO	WO 02/26246	04/04/02	WO			<input type="checkbox"/>	<input type="checkbox"/>
AP						<input type="checkbox"/>	<input type="checkbox"/>
AQ						<input type="checkbox"/>	<input type="checkbox"/>
AR							

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

AR	Brose et al., "BRAF and RAS Mutations in Human Lung Cancer and Melanoma", <i>Cancer Res</i> , Vol. 62, No. 23, pp. 6997-7000 (2002).
AS	Cohen et al., "BRAF Mutation in Papillary Thyroid Carcinoma", <i>J Natl Cancer Inst</i> , Vol. 95, No. 8, pp. 625-627 (2003).
AT	Edmunds et al., "Absence of BRAF Gene Mutations in Uveal Melanomas in Contrast to Cutaneous Melanomas", <i>Br J Cancer</i> , Vol. 88, No. 9, pp. 1403-1405 (2003).

EXAMINER

DATE CONSIDERED

\*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

## INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.  
ON/4-32701A  
APPLICATION NO.  
10/528,915  
APPLICANT  
David Bryant Batt  
FILING DATE  
JANUARY 5, 2006

Group

EXAMINER  
INITIAL

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

	DA	Kimura et al., "High Prevalence of <i>BRAF</i> Mutations in Thyroid Cancer: Genetic Evidence for Constitutive Activation of the RET/PTC-RAS-BRAF Signaling Pathway in Papillary Thyroid Carcinoma", <i>Cancer Res</i> , Vol. 63, No. 7, pp. 1454-1457 (2003).
	DB	Lang, Boxer and MacKie, "Absence of Exon 15 <i>BRAF</i> Germline Mutations in Familial Melanoma", <i>Hum Mutat</i> , Vol. 21, No. 3, pp. 327-330 (2003).
	DC	Mercer and Pritchard, "Raf Proteins and Cancer: B-Raf is Identified as a Mutational Target", <i>Biochim Biophys Acta</i> , Vol. 1653, No. 1, pp. 25-40 (2003).
	DD	Meyer et al., "Exclusion of <i>BRAF</i> <sup>V599E</sup> as a Melanoma Susceptibility Mutation", <i>Int J Cancer</i> , Vol. 106, No. 1, pp. 78-80 (2003).
	DE	Miwa et al., "Absence of Activating Mutations of the <i>RAF1</i> Protooncogene in Human Lung Cancer", <i>Biol Chem Hoppe Seyler</i> , Vol. 375, No. 10, pp. 705-709 (1994).
	DF	Naoki et al., "Missense Mutations of the <i>BRAF</i> Gene in Human Lung Adenocarcinoma", <i>Cancer Res</i> , Vol. 62, No. 23, pp. 7001-7003 (2002).
	DG	Pollock and Meltzer, "A Genome-Based Strategy Uncovers Frequent <i>BRAF</i> Mutations in Melanoma", <i>Cancer Cell</i> , Vol. 2, No. 1, pp. 5-7 (2002).
	DH	Pollock et al., "High Frequency of <i>BRAF</i> Mutations in Nevi", <i>Nat Genet</i> , Vol. 33, No. 1, pp. 19-20 (2003).
	DI	Satyamoorthy et al., "Constitutive Mitogen-Activated Protein Kinase Activation in Melanoma is Mediated by Both <i>BRAF</i> Mutations and Autocrine Growth Factor Stimulation", <i>Cancer Res</i> , Vol. 63, No. 4, pp. 756-759 (2003).
	DJ	Singer et al., "Mutations in <i>BRAF</i> and <i>KRAS</i> Characterize the Development of Low-Grade Ovarian Serous Carcinoma", <i>J Natl Cancer Inst</i> , Vol. 95, No. 6, pp. 484-486 (2003).
	DK	Tannapfel et al., "Mutations of the <i>BRAF</i> Gene in Cholangiocarcinoma but Not in Hepatocellular Carcinoma", <i>Gut</i> , Vol. 52, No. 5, pp. 706-712 (2003).
	DL	Yuen et al., "Similarity of the Phenotypic Patterns Associated with <i>BRAF</i> and <i>KRAS</i> Mutations in Colorectal Neoplasia", <i>Cancer Res</i> , Vol. 62, No. 22, pp. 6451-6455 (2002).
	DM	
	DN	
	DO	

EXAMINER

DATE CONSIDERED

\*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.